OptiNose, Inc. (OPTN) Financials

OPTN Assets vs Liabilities
DateAssetsLiabilities
March 31, 2025 114.9 million 176.2 million
Dec. 31, 2024 128.8 million 169.1 million
Sept. 30, 2024 131.0 million 172.1 million
June 30, 2024 131.9 million 174.7 million

OPTN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2025 1.9 million 1.4 million
Dec. 31, 2024 1.9 million 981000
Sept. 30, 2024 -8.9 million 1.3 million
June 30, 2024 -15.7 million 2.7 million

OPTN Net Income

No data available :(

OPTN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2025 72.9 million - 1.2 million
Dec. 31, 2024 84.5 million 1.2 million 2.5 million
Sept. 30, 2024 82.5 million - 1.0 million
June 30, 2024 91.4 million 126.6 million 2.2 million

OPTN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2025 11.7 million
Dec. 31, 2024 11.6 million
Sept. 30, 2024 174.4 million
June 30, 2024 150.7 million

OPTN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2025 - 760000 23.6 million -
Dec. 31, 2024 - 772000 19.3 million -
Sept. 30, 2024 21000 949000 19.5 million -
June 30, 2024 29000 928000 24.1 million -

OPTN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2025 18.5 million 1.8 million
Dec. 31, 2024 22.4 million 2.0 million
Sept. 30, 2024 20.4 million 2.1 million
June 30, 2024 20.5 million 2.0 million

OPTN Revenue by Segment
Graph available only for paid members. Upgrade to see it.

OPTN

Price: $9.60

52 week price:
4.82
20.03

Payout Ratio Range:
-320.30%
-38.34%

Earnings Per Share: -2.17 USD

P/E Ratio: -4.42

Exchange: NMS

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Country: United States

Volume: 133800

Ebitda: -13.0 million

Market Capitalization: 97.2 million

Links: